Showing 5791-5800 of 9331 results for "".
- New Study Seeks to Improve Skin Cancer Prevention in Young Adults Via a New Websitehttps://practicaldermatology.com/news/new-study-seeks-to-improve-skin-cancer-prevention-in-young-adults-via-a-new-website/2457539/Researchers out of Rutgers Cancer Institute of New Jersey and colleagues from across the country are conducting a study to evaluate the reach and effectiveness of an online program targeted at skin cancer prevention in young adults. Investigators are refining an existing website to
- RealSelf Forms Strategic Medical Advisory Councilhttps://practicaldermatology.com/news/realself-forms-strategic-medical-advisory-council/2457540/RealSelf, Inc. has formed a Strategic Medical Advisory Council with three operating boards. The RealSelf Strategic Advisory Council is made up of the Business Advisory Board, the Medical Review Advisory Board and the Industry Advisory Board, all of which are comprised of board-certified doctors a
- Hologic's Cynosure Division Launches TempSure Surgical RF Technology in North Americahttps://practicaldermatology.com/news/hologics-cynosure-division-launches-tempsure-surgical-rf-technology-in-north-america/2457541/Hologic, Inc.’s Cynosure division is launching the U.S. Food and Drug Administration (FDA)-cleared
- Almirall and X-Chem Team Up to Develop Oral Compounds for Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-and-x-chem-team-up-to-develop-oral-compounds-for-dermatological-diseases/2457545/Almirall, S.A. signed a collaborative research and license agreement with the X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases, a strategic area for Almirall. X-Chem, Inc. is a privately held biotechnology company focused on applying its indus
- AD, Suicidal Thoughts and Attempts Linkedhttps://practicaldermatology.com/news/ad-suicidal-thoughts-and-attempts-linked/2457543/Patients with eczema may be more likely to have suicidal thoughts and attempts compared to their counterparts without eczema, according to a new study in JAMA Dermatology. Res
- Dermatologists Need More Info About Cannabinoidshttps://practicaldermatology.com/news/dermatologists-need-more-info-about-cannabinoids/2457549/Dermatologists are interested in learning more about cannabinoids and recommending them to patients, according to a new survey in Journal of Drugs in Dermatology. However, many are concerned about th
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- Naked Eye, Smart Phone Apps May Miss Melanomashttps://practicaldermatology.com/news/naked-eye-smart-phone-apps-may-miss-melanomas/2457486/The naked eye alone is not enough to accurately diagnosis skin cancer and smart phone apps may also miss melanomas, according to a new review published in The Cochrane Library as part of a Special Collection of Coch
- New PsA Guidelines from National Psoriasis and Rheumatology Orgs Recommend Treat-to-Target Approachhttps://practicaldermatology.com/news/new-psa-guidelines-from-national-psoriasis-and-rheumatology-orgs-recommend-treat-to-target-approach/2457490/Newly released psoriatic Arthritis (PsA) treatment guidelines from the National Psoriasis Foundation (NPF) and the American College of Rheumatology (ACR) are calling for a treat-to-target approach for all patients with active PsA. What’s more, the guidelines co
- Crown Laboratories Acquires Select Healthcare Brands from GlaxoSmithKlinehttps://practicaldermatology.com/news/crown-laboratories-acquires-select-healthcare-brands-from-glaxosmithkline/2457492/Crown Laboratories, Inc. has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK). The acquired portfolio includes: PanOxyl® daily acne wash, Sarna® anti-itch lotion, Zeasorb® anti-fungal and prevention product, De